^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Mantle Cell Lymphoma
    Drug:lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    05/24/2022
    Excerpt:
    REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with...Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies...
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    06/14/2007
    Excerpt:
    Revlimid as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Mantle cell lymphoma: Other recommended regimens...Lenalidomide
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Lancet Haematol
    Title:

    Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial

    Published date:
    12/22/2020
    Excerpt:
    At a median follow-up of 38 months after randomisation (IQR 24–50), 3-year progression-free survival was 80% (95% CI 70–87) in the lenalidomide group versus 64% (53–73) in the observation group (log-rank test p=0·012; hazard ratio 0·51, 95% CI 0·30–0·87)...lenalidomide after autologous HSCT improved progression-free survival in patients with mantle cell lymphoma, highlighting the role of maintenance in mantle cell lymphoma.
    DOI:
    10.1016/S2352-3026(20)30358-6
    Trial ID:
    MCL0208